荆花胃康胶丸联合三联疗法治疗老年幽门螺杆菌感染慢性胃炎的疗效

目的了解荆花胃康胶丸联合三联疗法治疗老年幽门螺杆菌(Hp)感染慢性胃炎的临床效果。方法选取2010年2月至2013年1月160例老年慢性胃炎患者,采用随机数字表分为对照组和荆花胃康胶丸治疗组,每组80例;对照组采用兰索拉唑、阿莫西林与克拉霉素联合治疗,荆花胃康胶丸治疗组在对照组的治疗基础上加用荆花胃康胶丸,治疗4 w后观察两组患者Hp的根除率、临床症状缓解情况及不良反应的发生情况。结果对照组患者中59例(73.8%)Hp得到根除,67例(83.8%)慢性胃炎症状得到缓解,7例患者在治疗期间发生不良反应;荆花胃康胶丸治疗组77例(96.3%)Hp得到根除,71例(88.8%)慢性胃炎症状得到缓解,3例患者治疗期间出现不良反应,荆花胃康胶丸治疗组的Hp根除率与临床症状缓解率高于对照组(P<0.05),不良反应发生率低于对照组(P<0.05)。结论荆花胃康胶丸联合三联疗法能够提高Hp根除率和降低不良反应发生率,对老年Hp感染慢性胃炎的临床效果显著。     

小剂量奥美拉唑治疗功能性消化不良的临床研究

目的 评价小剂量奥美拉唑治疗功能性消化不良(FD)的疗效.方法 将2005年9月至2007年9月在辽宁省人民医院消化内科门诊就诊的260例FD患者随机分为2组,口服小剂量奥美拉唑148例(观察组),口服埃索美拉唑和多潘立酮共112例(对照组).疗程均为2周.观察两组患者胃部烧灼感、餐后饱胀、上腹痛及嗳气等症状改善程度.结果 两组治疗前后胃部烧灼感、上腹痛症状评分下降差异均有统计学意义(P＜0.01);嗳气症状评分下降差异有统计学意义(P＜0.05);餐后饱胀症状分级评分对照组治疗前后差异有统计学意义(P＜0.05).上述症状评分治疗后两组比较,差异均无统计学意义(P＞0.05).结论 小剂量奥美拉唑治疗FD疗效肯定,与埃索美拉唑和多潘立酮联合用药效果相近,而且用药不良反应少,可作为治疗FD首选用药.     

生物阻抗技术评价多潘立酮对功能性消化不良胃动力的影响

目的 研究多潘立酮对功能性消化不良(functional dyspepsia,FD)患者胃动力的影响.方法 应用胃动力检测系统检测2007年6月至2008年2月重庆医科大学附属第一医院消化门诊30例FD患者餐后胃动力,同步提取胃阻抗信号和胃电信号,并对FD患者进行症状评分,多潘立酮10 mg每日3次治疗1周后,复查餐后胃动力并再次症状评分.结果 经多潘立酮治疗后FD患者腹胀、腹痛、早饱、嗳气症状积分明显下降(P＜0.05),餐后不适综合征(PDS)组症状改善较明显(P＜0.05).胃电主功率百分比治疗后[(58.03±8.05)%]较治疗前[(52.07±7.01)%]有显著提高(P＜0.05).治疗前,PDS组和上腹疼痛综合征(EPS)组主功率百分比差异无统计学意义(P＞0.05);治疗后,PDS组主功率百分比[(46.50±4.08)%]显著高于EPS组[(41.99±3.10)%](P＜0.01);PDS和EPS两组各频段功率百分比治疗前后差异均无统计学意义(P＞0.05).结论 多潘立酮可改善FD患者的临床症状,恢复异常的胃电活动,阻抗胃动力紊乱并未完全恢复正常;经多潘立酮治疗后PDS组较EPS组阻抗胃动力紊乱改善较明显.     

达立通颗粒治疗功能性胃十二指肠病临床疗效观察

目的评价达立通治疗功能性胃十二指肠病的临床效果。方法72例功能性胃十二指肠病患者随机分为两组,每组36例。分别予口服达立通颗粒（6 g/次,3次/d）和莫沙比利（5 mg/次,3次/d）,比较两组治疗前后胃排空试验结果和消化不良症状积分,并评估达立通颗粒的疗效和安全性。结果治疗后两组患者餐后2 h胃排空率均有提高,但莫沙比利组治疗后胃排空率较达立通组显著提高（P〈0.05）。治疗后两组患者的症状总积分均较治疗前显著下降（P〈0.01）。达立通组餐后饱胀、上腹痛、嗳气的改善程度优于莫沙比利组（P〈0.01）。结论达立通治疗功能性胃十二指肠病改善消化不良症状方面优于莫沙比利,并具有良好的安全性。     

荆花胃康胶丸联合PPI三联疗法治疗Hp相关性慢性胃炎52例临床观察

[目的]观察荆花胃康胶丸联合PPI三联疗法对幽门螺杆菌(Hp)相关性慢性胃炎的治疗效果。[方法]将104例患者随机分为治疗组和对照组,治疗组给予兰索拉唑30mg bid+阿莫西林1 000mg bid+克拉霉素500mg bid+荆花胃康胶丸160mg tid,治疗10d后,再单独服用荆花胃康胶丸2周;对照组给予兰索拉唑30mg bid+阿莫西林1 000mg bid+克拉霉素500mg bid+枸橼酸铋钾220mg bid,治疗10d。比较2组治疗后的症状改善情况,以及停药28d后Hp的根除效果。[结果]在Hp根除方面,2组的根除率分别为84.4%、88.9%,差异无统计学意义;在症状改善方面,2组较前均有明显改善(P<0.05),其中荆花胃康胶丸组在改善上腹胀、嗳气、上腹痛方面优于含铋剂四联组(P<0.05)。[结论]2组根除Hp效果相当,但荆花胃康胶丸组在改善症状方面的效果更为明显。     

人参胃康片治疗糖尿病胃轻瘫疗效观察

[目的]观察人参胃康片治疗糖尿病胃轻瘫(DGP)的临床疗效。[方法]将60例DGP患者随机分为3组,各20例。治疗组予该院制剂人参胃康片,对照组予多潘立酮,安慰剂组予维生素B1治疗,疗程均为4周。观察3组治疗前后临床疗效、中医证候积分、胃排空率。[结果]总有效率治疗组80%、对照组75%、安慰剂组45%,前2组与安慰剂组比较差异有统计学意义(P0.05)。治疗组治疗后餐后饱胀、食欲减退、嗳气3种症状及对照组餐后饱胀的中医证候积分均有所改善,与治疗前比较均P0.05。治疗组和对照组治疗后胃排空时间明显缩短(P0.01),2组治疗后组间比较以及安慰剂组治疗前后比较差异均无统计学意义(P0.05)。3组用药前后血糖、尿常规、大便常规及肝肾功能均无异常,也未见不良反应发生。[结论]人参胃康片治疗DGP有较显著的疗效。     

马来酸曲美布汀与多潘立酮治疗老年功能性消化不良的疗效比较

目的探讨马来酸曲美布汀与多潘立酮治疗老年功能性消化不良(FD)患者的临床疗效。方法 160例老年FD患者按随机数字表法分为对照组和试验组各80例。对照组给予多潘立酮治疗,试验组给予马来酸曲美布汀治疗,两组均连续治疗4 w。比较两组临床疗效,评定并比较两组治疗前后的临床症状(早饱感、餐后饱胀感、上腹疼痛、上腹灼烧感)评分和水负荷量,观察并比较两组治疗期间口干、腹泻、腹痛、头晕等不良反应的发生情况。结果试验组总有效率明显高于对照组(P<0.05)。治疗后,两组各临床症状评分及总分均明显降低,且试验组降低更加明显(P<0.05)。试验组治疗后水负荷量明显增加,且明显高于对照组(P<0.05)。两组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。结论与多潘立酮比较,马来酸曲美布汀治疗老年FD患者的临床疗效显著,能够明显缓解临床症状,改善胃容受性扩张功能,不良反应发生率较低,值得临床推广应用。     

荆花胃康胶丸治疗HP相关性慢性胃炎的临床、病理研究

目的 观察荆花胃康胶丸治疗HP相关性胃炎的临床疗效。方法选取HP相关性慢性胃炎120例，随机分成荆花胃康胶丸治疗组和雷尼替丁胶囊对照组，对两组的临床症状、组织学改善情况，HP转阴率进行比较。结果荆花胃康胶丸治疗HP相关性慢性胃炎有较好的疗效。患者自觉症状减轻，组织学改善明显，部分患者HP转阴。结论荆花胃康胶丸是治疗HP相关性慢性胃炎的有效药物。     

多潘立酮对功能性消化不良患者阻抗式胃动力的影响

目的观察多潘立酮对功能性消化不良(FD)餐后不适综合征(PDS组)和上腹疼痛综合征(EPS组)临床症状和胃动力的影响。方法对2008年10月至2009年4月重庆医科大学附属第一医院消化内科门诊57例FD患者行症状分型和评分、检测餐后胃电和胃阻抗,多潘立酮10mg每日3次治疗2周和4周后,再次评分并复查胃动力。结果治疗2周后,PDS组和EPS组餐后饱胀不适、早饱感、上腹痛、上腹烧灼感症状较治疗前显著改善(P0.05);4周后除PDS组上腹烧灼感和EPS组早饱感、上腹痛外余症状均进一步改善(P0.05)。治疗前和治疗后2周及4周PDS组和EPS组的胃电中频百分比差异均有统计学意义(P0.05)。PDS组治疗2周后胃阻抗中频百分比较治疗前显著提高,4周后进一步提高(P0.05);治疗4周后,EPS组胃阻抗中频百分比显著高于治疗前和治疗后2周(P0.05)。结论多潘立酮治疗4周后FD患者的临床症状、胃电和胃阻抗显著改善,明显优于治疗后2周。     

多潘立酮联合复方消化酶治疗功能性消化不良84例

目的: 观察多潘立酮联合复方消化酶胶囊治疗功能性消化不良的临床疗效和安全性.方法: 84例功能性消化不良患者随机分为两组, 每组42例, 两组均口服多潘立酮片, 三餐饭前30 min服用10 mg; 试验组加服复方消化酶胶囊, 三餐饭后30 min服用1粒. 4 wk后观察疗效.结果: 试验组治疗总有效率明显优于对照组,分别为85.7%和61.9%( P<0.05). 对上腹痛、餐后饱胀、早饱、上腹烧灼感症状改善情况进行比较, 试验组治疗前后的症状总积分及症状改善有效率较对照组有显著性差异( P<0.05),而且起效时间明显缩短. 两组患者均未发现严重不良反应.结论: 多潘立酮联合复方消化酶胶囊治疗功能性消化不良的临床疗效明显优于单用促动力药多潘立酮.     

Changes in patients&rsquo; symptoms and gastric emptying after Helicobacter pylori treatment

AIM: To investigate the changes in clinical symptoms and gastric emptying and their association in functional dyspepsia (FD) patients. METHODS: Seventy FD patients were enrolled and divided into 2 groups Helicobacter pylori (H. pylori)-negative group (28 patients), and H. pylori-positive group (42 patients). Patients in the H. pylori-positive group were further randomly divided into groups: H. pylori-treatment group (21 patients) and conventional treatment group (21 patients). Seventy two healthy subjects were selected as the control group. The proximal and distal stomach area was measured by ultrasound immediately after patients took the test meal, and at 20, 40, 60 and 90 min; then, gastric half-emptying time was calculated. The incidence of symptoms and gastric half-emptying time between the FD and control groups were compared. The H. pylori-negative and conventional treatment groups were given conventional treatment: domperidone 0.6 mg/(kg/d) for 1 mo. The H. pylori-treatment group was given H. pylori eradication treatment + conventional treatment: lansoprazole 30 mg once daily, clarithromycin 0.5 g twice daily and amoxicillin 1.0 g twice daily for 1 wk, then domperidone 0.6 mg/(kg/d) for 1 mo. The incidence of symptoms and gastric emptying were compared between the FD and control groups. The relationship between dyspeptic symptoms and gastric half-emptying time in the FD and control groups were analyzed. Then total symptom scores before and after treatment and gastric half-emptying time were compared among the 3 groups. RESULTS: The incidence of abdominal pain, epigastric burning sensation, abdominal distension, nausea, belching, and early satiety symptoms in the FD group were significantly higher than in the control group (50.0% vs 20.8%; 37.1% vs 12.5%; 78.6% vs 44.4%; 45.7% vs 22.2%; 52.9% vs 15.3%; 57.1% vs 19.4%; all P < 0.05). The gastric half-emptying times of the proximal end, distal end, and the whole stomach in the FD group were slower than in the control group (93.7 ± 26.2 vs 72.0 ± 14.3; 102.2 ± 26.4 vs 87.5 ± 18.2; 102.1 ± 28.6 vs 78.3 ± 14.1; all P < 0.05). Abdominal distension, belching and early satiety had an effect on distal gastric half-emptying time (P < 0.05). Abdominal distension and abdominal pain had an effect on the gastric half-emptying time of the whole stomach (P < 0.05). All were risk factors (odds ratio > 1). The total symptom score of the 3 groups after treatment was lower than before treatment (P < 0.05). Total symptom scores after treatment in the H. pylori-treatment group and H. pylori-negative group were lower than in the conventional treatment group (5.15 ± 2.27 vs 7.02 ± 3.04, 4.93 ± 3.22 vs 7.02 ± 3.04, All P < 0.05). The gastric half-emptying times of the proximal end, distal end, and the whole stomach in the H. pylori-negative and H. pylori-treatment groups were shorter than in the conventional treatment group (P < 0.05). CONCLUSION: FD patients have delayed gastric emptying. H. pylori infection treatment helps to improve symptoms of dyspepsia and is a reasonable choice for treatment in clinical practice.     

功能性消化不良患者胃排空与症状的相关性及影响因素分析

目的了解胃排空异常与消化不良症状的相关性,分析影响功能性消化不良（FD）患者胃排空的因素。方法纳入32例FD患者。量化记录餐后上腹饱胀、上腹痛、上腹烧灼感、早饱、嗳气、恶心、呕吐7组症状及静息心率。以心率的中位数将其转化为二分类变量进行非条件Logistic回归分析统计。运用核素闪烁法检测空腹固体试餐,试餐参考美国胃肠动力学会、神经胃肠学会及核医学联合推荐的标准低脂试餐以及诊断标准。结果 32例FD患者,8例（25%）T1/2延迟,7例（21.88%）Retention%2 h增加,Retention%1 h均在正常范围内。Retention%2 h正常组与Retention%2 h增加组以及T1/2正常组与T1/2延长组之间,心率均存在显著差异（P=0.031,P=0.022）,心率与Retention%2 h、T1/2存在正相关（r=0.448,P=0.01;r=0.423,P=0.016）。在控制了性别、年龄及其他症状因素的影响下,心率〉70 bpm是Retention%2 h增加、T1/2延长的独立因素（OR=12.378,P=0.042;OR=8.180,P=0.072）。在Retention%2 h正常组与Retention%2 h增加组之间恶心症状指数有显著差异（P=0.003）,恶心与Retention%2 h、T1/2存在正相关（r=0.527,P=0.002;r=0.381,P=0.032）。结论心率、恶心症状与功能性消化不良患者的胃排空存在一定相关性,在控制了性别、年龄、BMI及其他症状的因素影响下,静息心率增加、出现恶心症状可能是胃排空延缓的独立因素。     

复方阿嗪米特肠溶片治疗消化不良的多中心、随机、双盲、安慰剂平行对照临床研究

背景:复方阿嗪米特肠溶片(商品名:泌特)含阿嗪米特和多种消化酶,国外用于治疗慢性消化不良已有多年,但迄今为止在国内尚无多中心、随机、安慰剂平行对照研究.目的:评价应用复方阿嗪米特肠溶片治疗慢性消化不良的临床疗效、安全性和依从性.方法:采用多中心、随机、双盲、安慰剂平行对照临床研究.上海市11个临床中心共纳入消化不良患者203例,随机分为两组,资料完整并纳入统计分析者191例,治疗组86例,对照组105例.餐后分别立即服用复方阿嗪米特肠溶片或安慰剂2片,每日3次,疗程2周.治疗前后和治疗期间每天分别评估各消化不良症状的积分、药物副作用和患者的依从情况.结果:两组消化不良患者的年龄、性别、疾病类别和消化不良症状积分均有较好的匹配性,且均完成了研究规定的疗程.与对照组相比,治疗组治疗1周后各消化不良症状积分均小于对照组,腹胀、嘈杂和总症状积分显著下降(P<0.05);治疗2周后,除便秘症状(P=0.214)外,治疗组食欲不振、腹胀、腹痛、嗳气、恶心、嘈杂、腹泻症状和症状总积分均显著低于对照组(P均＜0.05).治疗1周和2周后,治疗组各消化不良症状积分和症状总积分改善率均显著高于对照组(P<0.0001).结论:复方阿嗪米特肠溶片治疗各种病因相关性消化不良安全有效,依从性好,无严重不良反应.     

Functional dyspepsia symptoms, gastric emptying and satiety provocative test: analysis of relationships

BACKGROUND: The correlation between symptoms and observed impaired function in functional dyspepsia is still inconsistent. The aims of the study were to obtain a measure of satiety by a meal test; to verify whether this compares with severity of symptoms assessed using a reproducible questionnaire; and to correlate the parameters of satiety test and gastric emptying with all the dyspeptic symptoms. METHODS: Fifty-two functional dyspepsia patients reported their symptoms on a standardized questionnaire that considered belching, bloating, early satiety, epigastric pain and burning, nausea, postprandial fullness and vomiting. They were monitored for gastric emptying of a solid caloric meal using a radionuclide technique and underwent a test to quantify meal-induced satiety by a liquid caloric meal. RESULTS: The number of kilocalories ingested during the satiety test until the occurrence of maximum satiety in healthy subjects was 110% higher than in the dyspeptic group (mean +/- s(mean): 1110 +/- 23 versus 532 +/- 56; P < 0.01). We found a significant positive correlation between gastric emptying rate and kcal of the satiety test (P < 0.01; r = 0.428). Logistic regression showed a significant inverse association between severity of early satiety-coded as absent, mild, moderate or severe, kcal of meal test (P = 0.01), and gastric emptying lag phase (P = 0.03). Bloating was associated directly with t(1/2) of gastric emptying (P = 0.03) and inversely with lag phase (P = 0.02). CONCLUSIONS: The satiety test gives a fine numerical measure of satiety and confirms the results of a symptoms questionnaire. Our study showed an indirect correlation between severity of early satiety--as measured by the satiety test, and gastric emptying rate, as well as an association between bloating and delayed gastric emptying.     

胃排空障碍与功能性消化不良相关性的研究

目的：探讨胃排空障碍与功能性消化不良（FD）之间的关系。方法：以双核素标记试餐SPECT技术检测了22例FD患者的液、固体食物胃排空和食物胃内分布，并以实时超声检测了72例FD患者在西沙必利治疗前后的液体胃排空变化，分析这些变化与症状积分变化的相关性．结果：68．2％的FD患者存在胃排空障碍，以固体胃排空延迟为主，单纯液体排空障碍较少；摄食后比对照组有更多的食物滞留于远端胃内，然而，延迟的胃排空和改变了的固体食物胃内分布与FD的主要症状无显著相关性。西沙必利明显缩短FD患者的液体胃排空时间，改善其中部分患者的临床症状，而另一部分患者的症状无明显缓解．结论：西沙必利改善FD症状并非完全依赖于其促排空效应，胃排空障碍与FD之间缺乏必然的联系，它们可能是同一病生基础的两种不同表现．     

伊托必利治疗功能性消化不良重叠便秘型肠易激综合征疗效观察

目的 观察伊托必利治疗功能性消化不良(FD)重叠便秘型肠易激综合征(C-IBS)患者的疗效.方法 将符合FD标准及重叠C-IBS患者分为FD治疗组(40例)、FD观察组(20例)、FD重叠C-IBS治疗组(40例)和FD重叠C-IBS观察组(20例),FD治疗组和FD重叠C-IBS治疗组均给予伊托必利100 rag/次,每日3次,疗程8周.观察并记录4组患者上腹饱胀、早饱、腹痛等症状及C-IBS患者便秘改善情况.FD治疗组和FD重叠C-IBS治疗组于治疗前及治疗后2周进行胃排空试验.结果 FD治疗组和FD重叠C-IBS治疗组患者腹痛、上腹饱胀、早饱等症状均有不同程度改善,其中FD重叠C-IBS治疗组改善程度更为明显,且排便情况亦有显著改善.B超监测胃排空显示,与观察组相比,FD治疗组和FD重叠C-IBS治疗组患者治疗后胃窦收缩幅度及胃排空时间均有显著改善(P<0.05).结论 伊托必利治疗FD有效,尤其是对FD重叠C-IBS治疗组的疗效优于FD治疗组.     

左旋多巴治疗非溃疡性消化不良

鉴于左旋多巴(L—dopa)对胃粘膜有保护作用,以及对胃肠运动的调节,本研究对142例NUD患者进行了疗效观察,其中治疗组56例,包括以腹痛返酸为主的A组及腹胀早饱主为的B组。口服L—dopa0.25tid。对照组90例,分为3组,分别口服Domperidone10mg tid.Vit B_150mg tid及Paspertin4mg tid,疗程4周。结果显示:L—dopa对于缓解上腹痛和返酸症状明显优于其它药物组,P<0.01;对腹胀的缓解与Domperidone及Vit B_1相近;而副作用仅轻微恶心。本研究建议对于NUD病人治疗前做胃排空功能检测,胃排空过快者用L—dopa治疗,胃排空延缓者用Domperidone或其它促胃动力药治疗,而不是千篇一律用Domperidone治疗。     

Effect of domperidone therapy on nocturnal dyspeptic symptoms of functional dyspepsia patients

AIM:To investigate the incidence of nocturnal dyspeptic symptoms in patients with functional dyspepsia(FD) and whether prokinetic drugs can alleviate them. METHODS:Eighty-five consecutive Chinese patients with FD were included in this study.One week after single-blinded placebo run-in treatment,baseline nocturnal intragastric pH,bile reflux and nocturnal dyspeptic symptoms of eligible patients,including epigastric pain or discomfort,abdominal distention and belching, were investigated with questionnaires.Pa...     

健脾理气法治疗功能性消化不良脾虚气滞证及对核素胃排空的影响

[目的]评价健脾理气法治疗脾虚气滞证功能性消化不良的临床疗效及其对胃排空的影响.[方法]采用随机单盲阳性药对照方法,对纳入治疗的78例脾虚气滞证功能性消化不良患者随机分为中药治疗组(40例)和西药治疗组(38例),分别给予健脾理气方和多潘立酮治疗,治疗疗程均为4周.分别在治疗前、治疗后、治疗结束后1个月(随访时),对患者的总体症状积分、单项症状积分、核素胃排空指标进行评价.[结果]①总体症状疗效评价:中药治疗组治疗后有效率85.00％,明显优于西药治疗组(68.42％),2组比较差异有统计学意义(P＜0.05).②中药治疗组对上腹痛、上腹烧灼感、餐后饱胀不适、早饱感4个主要临床症状的改善优于西药治疗组(P＜0.05).③胃排空试验评价:中药治疗组治疗后第30、45、60、75、90 min 5个时相的胃排空率与西药治疗组比较,均差异有统计学意义(P＜0.05).[结论]健脾理气方可改善脾虚气滞证功能性消化不良患者的临床症状,并可加快胃排空功能.     

Lack of Relationship Between Chronic Upper Abdominal Symptoms and Gastric Function in Functional Dyspepsia

To determine the relationship between gastric function and upper abdominal sensations we studied sixty FD patients (43 female). All patients underwent three gastric function tests: ¹³C octanoic gastric emptying test, three-dimensional ultrasonography (proximal and distal gastric volume), and the nutrient drink test. Upper abdominal sensations experienced in daily life were scored using questionnaires. Impaired proximal gastric relaxation (23%) and a delayed gastric emptying (33%) are highly prevalent in FD patients; however, only a small overlap exists between the two pathophysiologic disorders (5%). No relationship was found between chronic upper abdominal symptoms and gastric function (proximal gastric relaxation, gastric emptying rate, or drinking capacity) (all P > 0.01). Proximal gastric relaxation or gastric emptying rate had no effect on maximum drinking capacity (P > 0.01). The lack of relationship between chronic upper abdominal sensations and gastric function questions the role of these pathophysiologic mechanisms in the generation of symptoms.